Evidence map›Paper›PMID 40544177›Full record

ArticleNPJ breast cancer2025

The MBCRC Advocate Researcher Program (MARP): connecting advocates and researchers as collaborative partners in cancer research.

Hillary S Andrews, Igor L Bado, Amy Beumer, Isaac S Chan, Janice Cowden, Debbie Denardi, Gloria V Echeverria, Brooke L Gates, Marybeth Gilliam, Christine Hodgdon and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Hillary S AndrewsFriends of Cancer Research, Washington, DC, USA. handrews@focr.org.
Igor L BadoIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Amy BeumerMETAvivor and Project Life, Mason, OH, USA.
Isaac S ChanUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
Janice CowdenIndependent Patient Advocate, Bradenton, FL, USA.
Debbie DenardiIndependent Patient Advocate, North Miami Beach, FL, USA.
Gloria V EcheverriaBaylor College of Medicine, Houston, TX, USA.
Brooke L GatesUniversity of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Marybeth GilliamOutperform Cancer, Charlotte, VT, USA.
Christine HodgdonGRASP, Baltimore, MD, USA.
Adrian V LeeUniversity of Pittsburgh, Pittsburgh, PA, USA.
Joan MancusoIndependent Breast Cancer Advocate, Philadelphia, PA, USA.
Julia MauesGRASP, Washington, DC, USA.
Steffi OesterreichUniversity of Pittsburgh, Pittsburgh, PA, USA.
Michael PapanicolaouAlbert Einstein College of Medicine, New York, NY, USA.
Katherine E PendletonBaylor College of Medicine, Houston, TX, USA.
Bob RiterIndependent Patient Advocate, Ithaca, NY, USA.
Kelly ShanahanMETAvivor, Lake Tahoe, CA, USA.
Anh M Tran-HuynhBaylor College of Medicine, Houston, TX, USA.
Pavitra ViswanathUniversity of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Stephanie WalkerIndependent Patient Advocate, Tarboro, NC, USA.
Alana L WelmUniversity of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
Michelle M WilliamsUniversity of Pittsburgh, Pittsburgh, PA, USA.
Garhett L WyattTexas A&M University, College Station, TX, USA.
Josh NewbyBaylor College of Medicine, Houston, TX, USA.

Funding

Metabolic adaptation in residual triple negative breast cancer following chemotherapyR37CA269783 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Gloria Vittone Echeverria · 2023 to 2026
$2.1M
NCI NIH HHS R37 CA269783
6 · The paper itself

Abstract

Involving patient advocates as partners in cancer research improves research and provides favorable experiences for both the researcher and the advocate. Previous work demonstrates challenges to establishing relationships between researchers and advocates, including uncertainty about why the relationships are necessary, how to establish them, what to say, and how they should be structured. To overcome these challenges, we established the Metastatic Breast Cancer Research Conference (MBCRC) Advocate Researcher Program (MARP) at the MBCRC in 2023. We outline the approach to the program to serve as a model for others interested in performing similar activities and report findings from surveys to establish evidence about the value of these relationships. The program connected 21 pairs of researchers and advocates, and participants responded to surveys about their experience, largely describing positive outcomes. Our hope is that a program like this could be used at any cancer conference in the future as we continue to encourage advocates and researchers to work together.

Identifiers

PMID40544177
PMCPMC12182560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.